Literature DB >> 21426261

α(1)-antitrypsin deficiency and inflammation.

Ugo I Ekeowa1, Stefan J Marciniak, David A Lomas.   

Abstract

α(1)-antitrypsin deficiency is an autosomal recessive disorder that results from point mutations in the SERPINA1 gene. The Z mutation (Glu342Lys) accounts for the majority of cases of severe α(1)-antitrypsin deficiency. It causes the protein to misfold into ordered polymers that accumulate within the endoplasmic reticulum of hepatocytes. It is these polymers that form the periodic acid Schiff positive inclusions that are characteristic of this condition. These inclusions are associated with neonatal hepatitis, cirrhosis and hepatocellular carcinoma. The lack of circulating α(1)-antitrypsin exposes the lungs to uncontrolled proteolytic attack and so can predispose the Z α(1)-antitrypsin homozygote to early-onset emphysema. α(1)-antitrypsin polymers can also form in extracellular tissues where they activate and sustain inflammatory cascades. This may provide an explanation for both progressive emphysema in individuals who receive adequate replacement therapy and the selective advantage associated with α(1)-antitrypsin deficiency. Therapeutic strategies are now being developed to block the aberrant conformational transitions of mutant α(1)-antitrypsin and so treat the associated disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21426261     DOI: 10.1586/eci.10.95

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  9 in total

Review 1.  Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond.

Authors:  Chunyang Li; Shi-Yong Sun; Fadlo R Khuri; Runzhao Li
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

2.  Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.

Authors:  Marion Bouchecareilh; Darren M Hutt; Patricia Szajner; Terence R Flotte; William E Balch
Journal:  J Biol Chem       Date:  2012-09-20       Impact factor: 5.157

Review 3.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

4.  Longer telomere length in COPD patients with α1-antitrypsin deficiency independent of lung function.

Authors:  Aabida Saferali; Jee Lee; Don D Sin; Farshid N Rouhani; Mark L Brantly; Andrew J Sandford
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

5.  α1-Antitrypsin promotes SPLUNC1-mediated lung defense against Pseudomonas aeruginosa infection in mice.

Authors:  Di Jiang; Rebecca Persinger; Qun Wu; Ashley Gross; Hong Wei Chu
Journal:  Respir Res       Date:  2013-11-09

Review 6.  Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Authors:  Govindarajan Thangavelu; Bruce R Blazar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

7.  Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation.

Authors:  Zhenying Zhao; Yingbo Miao; Pengwei Pan; Binfeng Cheng; Gang Bai; Hong Wu
Journal:  BMC Complement Altern Med       Date:  2013-08-06       Impact factor: 3.659

8.  iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure.

Authors:  Liang Peng; Jing Liu; Yang-Mei Li; Zhan-Lian Huang; Pei-Pei Wang; Yu-Bao Zheng; Yun-Peng Hua; Zhi-Liang Gao
Journal:  Exp Ther Med       Date:  2015-09-04       Impact factor: 2.447

9.  Therapeutic potential of alpha-1 antitrypsin in human disease.

Authors:  Minsun Kim; Qing Cai; Youngman Oh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2018-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.